Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Stock Has Average Price Target of $40.60 According to Brokerages

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report) has earned an average rating of “Moderate Buy” from the thirteen research firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $40.60.

Several equities analysts have weighed in on the company. JPMorgan Chase & Co. reduced their price objective on Olema Pharmaceuticals from $52.00 to $46.00 and set an “overweight” rating for the company in a report on Thursday, August 13th. HC Wainwright lowered their target price on Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a research note on Tuesday, August 11th. Wall Street Zen cut Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 25th. Weiss Ratings raised Olema Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, September 21st. Finally, Stifel Nicolaus cut their price target on Olema Pharmaceuticals from $48.00 to $30.00 and set a “buy” rating for the company in a research note on Monday, September 14th.

View Our Latest Analysis on Olema Pharmaceuticals

Institutional Investors Weigh In On Olema Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OLMA. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Olema Pharmaceuticals in the 3rd quarter worth approximately $39,000. Quantbot Technologies LP purchased a new stake in shares of Olema Pharmaceuticals in the second quarter worth $77,000. E Fund Management Co. Ltd. bought a new stake in Olema Pharmaceuticals during the second quarter valued at $133,000. China Universal Asset Management Co. Ltd. boosted its stake in Olema Pharmaceuticals by 14.8% during the third quarter. China Universal Asset Management Co. Ltd. now owns 15,965 shares of the company’s stock valued at $136,000 after buying an additional 2,064 shares during the period. Finally, Canada Pension Plan Investment Board bought a new stake in Olema Pharmaceuticals during the second quarter valued at $144,000. 91.78% of the stock is currently owned by institutional investors.

Olema Pharmaceuticals Stock Performance

Shares of NASDAQ:OLMA traded up $0.04 during midday trading on Friday, reaching $7.56. The company had a trading volume of 1,696,514 shares, compared to its average volume of 1,438,241. The company’s 50 day moving average price is $8.18 and its 200 day moving average price is $13.19. The company has a current ratio of 6.12, a quick ratio of 8.86 and a debt-to-equity ratio of 0.01. The stock has a market cap of $662.33 million, a P/E ratio of -3.20 and a beta of 2.12. Olema Pharmaceuticals has a 52-week low of $6.24 and a 52-week high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA – Get Free Report) last posted its quarterly earnings results on Tuesday, November 10th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.09). As a group, sell-side analysts anticipate that Olema Pharmaceuticals will post -2.53 EPS for the current fiscal year.

Olema Pharmaceuticals Company Profile

(Get Free Report)

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for women’s cancers, particularly breast cancer. The company’s research centers on treatments that target pathways involved in hormone-sensitive tumors. Its lead candidate, palazestrant (OP-1250), is an oral therapy designed to act as both a selective estrogen receptor degrader and a complete estrogen receptor antagonist. Olema has studied it as a potential treatment for estrogen receptor–positive breast cancer, including in combination with other cancer medicines.

See Also

Analyst Recommendations for Olema Pharmaceuticals (NASDAQ:OLMA)

Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.